DK1408109T3 - Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel - Google Patents

Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel

Info

Publication number
DK1408109T3
DK1408109T3 DK02746067T DK02746067T DK1408109T3 DK 1408109 T3 DK1408109 T3 DK 1408109T3 DK 02746067 T DK02746067 T DK 02746067T DK 02746067 T DK02746067 T DK 02746067T DK 1408109 T3 DK1408109 T3 DK 1408109T3
Authority
DK
Denmark
Prior art keywords
protein
aging
cells
screening
aging agent
Prior art date
Application number
DK02746067T
Other languages
English (en)
Inventor
Fuyuki Ishikawa
Original Assignee
Fuyuki Ishikawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuyuki Ishikawa filed Critical Fuyuki Ishikawa
Application granted granted Critical
Publication of DK1408109T3 publication Critical patent/DK1408109T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating And Analyzing Materials By Characteristic Methods (AREA)
DK02746067T 2001-07-16 2002-07-15 Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel DK1408109T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001215576 2001-07-16
JP2001286412 2001-09-20
PCT/JP2002/007182 WO2003008577A1 (fr) 2001-07-16 2002-07-15 Nouvelles cellules transformees, methode de criblage d'agent anti-vieillissement et agents anti-vieillissement

Publications (1)

Publication Number Publication Date
DK1408109T3 true DK1408109T3 (da) 2008-10-06

Family

ID=26618801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02746067T DK1408109T3 (da) 2001-07-16 2002-07-15 Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel

Country Status (8)

Country Link
US (1) US7291499B2 (da)
EP (1) EP1408109B1 (da)
JP (1) JPWO2003008577A1 (da)
AT (1) ATE400649T1 (da)
CA (1) CA2454873C (da)
DE (1) DE60227524D1 (da)
DK (1) DK1408109T3 (da)
WO (1) WO2003008577A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045334A (ja) * 2009-08-28 2011-03-10 Kyushu Univ 細胞老化関連因子
FR2971792B1 (fr) * 2011-02-18 2017-06-23 Isp Investments Inc Methode in vitro pour identifier des agents modulateurs de la senescence cellulaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09271395A (ja) * 1996-04-02 1997-10-21 Nippon Zoki Pharmaceut Co Ltd 内皮細胞を用いたスクリーニング法
WO1997044467A1 (en) 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
WO1998005761A1 (en) * 1996-08-07 1998-02-12 The General Hospital Corporation Age-1 polypeptides and related molecules and methods
SG94355A1 (en) * 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
JP4588215B2 (ja) 1998-06-24 2010-11-24 ユニバーシティー オブ ダンディー ポリペプチド、ポリヌクレオチド及びそれらの用途
EP1091960A1 (en) 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents

Also Published As

Publication number Publication date
JPWO2003008577A1 (ja) 2004-11-11
CA2454873C (en) 2013-10-01
EP1408109A4 (en) 2005-02-16
ATE400649T1 (de) 2008-07-15
EP1408109B1 (en) 2008-07-09
WO2003008577A1 (fr) 2003-01-30
US20050288216A1 (en) 2005-12-29
US7291499B2 (en) 2007-11-06
DE60227524D1 (de) 2008-08-21
CA2454873A1 (en) 2003-01-30
EP1408109A1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
Kenny et al. Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis
Harwood et al. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro–in vivo extrapolation of oral drug absorption
Hirrlinger et al. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells
Feldmann Jr et al. Stem cell proteomes: a profile of human mesenchymal stem cells derived from umbilical cord blood
Yammani et al. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products
Chen et al. Quantitative proteomic analysis of the secretory proteins from rat adipose cells using a 2D liquid chromatography− MS/MS approach
Huesgen et al. N‐and C‐terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification
Bu et al. High‐throughput cytochrome P450 (CYP) inhibition screening via a cassette probe‐dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1
DK1766400T3 (da) Fremgangsmåde til at udföre fuldblodsanalyser
Lebrin et al. A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit α
IS7611A (is) Örfylki og aðferð til þess að framkvæma blöndunarhvörf fyrir fjölda sýna á einu örfylki
DE60330248D1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
DK1198585T3 (da) Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler
Adachi et al. Proteome-wide discovery of unknown ATP-binding proteins and kinase inhibitor target proteins using an ATP probe
JP2009539377A5 (da)
DK1745295T3 (da) Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
BRPI0512798A (pt) molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse
Huo et al. p53-independent induction of p21waf1/cip1 contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells
Thevis et al. Proteases in doping control analysis
Kjellerup et al. Pro‐inflammatory cytokine release in keratinocytes is mediated through the MAPK signal‐integrating kinases
DK1408109T3 (da) Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel
Armbrust et al. Early gene expression of hepatocyte growth factor in mononuclear phagocytes of rat liver after administration of carbon tetrachloride
DK0750637T3 (da) CAI resistens, som koder for et protein, samt anvendelse deraf
WO2004078131A3 (en) Evaluating effects of exposure conditions on drug samples over time